Scarica l'app Stockscreener
6.9659
5.28%
-0.3841
Precedente Chiudi:
$7.35
Aprire:
$7.31
Volume 24 ore:
2.08M
Relative Volume:
0.85
Capitalizzazione di mercato:
$1.11B
Reddito:
$405.76M
Utile/perdita netta:
$7.98M
Rapporto P/E:
139.32
EPS:
0.05
Flusso di cassa netto:
$77.47M
1 W Prestazione:
+2.39%
1M Prestazione:
-5.66%
6M Prestazione:
-33.82%
1 anno Prestazione:
-41.54%
Intervallo 1D:
$6.90
$7.52
Intervallo di 1 settimana:
$6.63
$7.52
Portata 52W:
$6.04
$15.38
Certara Inc Stock (CERT) Company Profile
Nome
Certara Inc
Settore
Industria
Telefono
(415) 237-8272
Indirizzo
4 RADNOR CORPORATE CENTER, SUITE 350, RADNOR
Compare CERT vs VEEV, TEM, BTSG, HQY, WAY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CERT
Certara Inc
|
6.96 | 1.17B | 405.76M | 7.98M | 77.47M | 0.05 |
|
VEEV
Veeva Systems Inc
|
194.69 | 30.98B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
51.64 | 9.17B | 1.27B | -245.03M | -245.36M | -1.4071 |
|
BTSG
Brightspring Health Services Inc
|
41.23 | 7.57B | 11.99B | 24.18M | 234.31M | 0.2956 |
|
HQY
Healthequity Inc
|
80.22 | 6.93B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
26.61 | 5.16B | 906.14M | -52.62M | 89.62M | -0.3621 |
Certara Inc Stock (CERT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-11-21 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-11-13 | Iniziato | BMO Capital Markets | Market Perform |
| 2025-09-29 | Iniziato | Craig Hallum | Buy |
| 2025-07-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2025-05-08 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-02-27 | Iniziato | TD Cowen | Buy |
| 2024-09-27 | Aggiornamento | UBS | Neutral → Buy |
| 2024-04-10 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-04-04 | Iniziato | JMP Securities | Mkt Perform |
| 2024-02-26 | Iniziato | Leerink Partners | Market Perform |
| 2023-12-07 | Iniziato | UBS | Neutral |
| 2023-12-05 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2023-08-22 | Downgrade | Jefferies | Buy → Hold |
| 2023-08-10 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-04-12 | Iniziato | Stephens | Overweight |
| 2023-04-03 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-12-14 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-09-08 | Iniziato | Berenberg | Buy |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-07-01 | Iniziato | Piper Sandler | Overweight |
| 2022-01-11 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-08-05 | Ripresa | Credit Suisse | Neutral |
| 2021-07-23 | Iniziato | Robert W. Baird | Outperform |
| 2021-03-03 | Iniziato | Barclays | Overweight |
| 2021-01-06 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-01-05 | Iniziato | BofA Securities | Buy |
| 2021-01-05 | Iniziato | Credit Suisse | Neutral |
| 2021-01-05 | Iniziato | Jefferies | Hold |
| 2021-01-05 | Iniziato | William Blair | Outperform |
Mostra tutto
Certara Inc Borsa (CERT) Ultime notizie
Certara (CERT) Gains FDA Acceptance for PBPK Modeling in Drug Ap - GuruFocus
Certara, Inc. (CERT) Stock Analysis: Exploring a 38% Potential Upside in Health Information Services - DirectorsTalk Interviews
CERT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Certara Simcyp® simulator results replace ten human trials for chronic myeloid leukemia (CML) therapy asciminib - marketscreener.com
Certara Simcyp Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib - Bitget
Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib - The Manila Times
FDA accepts virtual-patient data so leukemia drug avoids 10 trials - Stock Titan
Certara, Inc. $CERT Stock Holdings Boosted by Roubaix Capital LLC - MarketBeat
Certara Earnings Call: Software Strength Amid Transition - The Globe and Mail
Certara (CERT) director granted 5,547 restricted stock units - Stock Titan
Certara (CERT) director Arjun Bedi submits initial Form 3 insider filing - Stock Titan
Certara (CERT) Is Up 9.6% After Calling 2026 a Transition Year With Slower Growth Guidance - Sahm
Discipline and Rules-Based Execution in CERT Response - Stock Traders Daily
Certara, Inc. Hits 52-Week Low at USD 6.04 Amid Market Struggles - Markets Mojo
Certara (NASDAQ:CERT) Trading 6.1% HigherHere's What Happened - MarketBeat
Certara (CERT) Faces Downgrade Amid Strategic Uncertainty - GuruFocus
Certara (NASDAQ:CERT) Given New $8.00 Price Target at Barclays - MarketBeat
Certara stock downgraded at Craig-Hallum on growth concerns By Investing.com - Investing.com Canada
Certara stock downgraded at Craig-Hallum on growth concerns - Investing.com
Certara (NASDAQ:CERT) Rating Lowered to "Hold" at Craig Hallum - MarketBeat
Drug development firm Certara lines up three March investor talks - Stock Titan
Morgan Stanley Cuts Price Target on Certara to $11 From $12, Keeps Equalweight Rating - marketscreener.com
Decoding Certara Inc (CERT): A Strategic SWOT Insight - GuruFocus
Certara Q4 2025 slides: services growth offsets software weakness By Investing.com - Investing.com Australia
Certara stock hits 52-week low at 6.26 USD By Investing.com - Investing.com Australia
Certara (NASDAQ:CERT) Issues Earnings Results - MarketBeat
Leerink Maintains Outperform on Certara, Inc. (CERT) Feb 26 2026 PT $10 - Meyka
Certara to Participate in Upcoming Investor Conferences - Bitget
Certara Inc reports results for the quarter ended December 31Earnings Summary - TradingView
TD Cowen cuts Certara stock price target on macro headwinds - Investing.com
TD Cowen cuts Certara stock price target on macro headwinds By Investing.com - Investing.com South Africa
Leerink cuts Certara stock price target on weak bookings, guidance By Investing.com - Investing.com South Africa
Certara outlines flat to 4% 2026 revenue growth as new CEO signals operational overhaul and $10M cost avoidance - MSN
Leerink cuts Certara stock price target on weak bookings, guidance - Investing.com
Certara Q4 2025 slides: services growth offsets software weakness - Investing.com
Certara Q4 Earnings Call Highlights - MarketBeat
CERT: 2026 guidance targets flat to 4% revenue growth amid operational changes and AI-driven focus - TradingView
Earnings call transcript: Certara Q4 2025 reports mixed results - Investing.com
Certara (NASDAQ:CERT) Sets New 52-Week Low on Disappointing Earnings - MarketBeat
Earnings call transcript: Certara Q4 2025 reports mixed results By Investing.com - Investing.com Canada
CERT: 2025 revenue grew 9%, but 2026 guidance is flat to 4% amid operational and market shifts - TradingView
Certara stock hits 52-week low at 6.26 USD - Investing.com
Certara, Inc. (CERT) Q4 Results Fall Short of Expectations - Bitget
Certara earnings on deck: New CEO faces test as estimates slide - Investing.com Nigeria
Certara earnings on deck: New CEO faces test as estimates slide By Investing.com - Investing.com South Africa
Certara, Inc.Common Stock (NQ: CERT - FinancialContent
Certara, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:CERT) 2026-02-26 - Seeking Alpha
Certara (NASDAQ:CERT) Issues FY 2026 Earnings Guidance - MarketBeat
Certara, Inc. (CERT) Q4 Earnings Lag Estimates - Yahoo Finance
Certara, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Certara Q4 Adjusted Earnings Fall, Revenue Rises; 2026 Outlook Set - marketscreener.com
Certara Inc Azioni (CERT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.27%
3.54%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):